Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study

dc.contributor.authorRini, Brian I.
dc.contributor.authorHalabi, Susan
dc.contributor.authorBarrier, Robert
dc.contributor.authorMargolin, Kim A.
dc.contributor.authorAvigan, David
dc.contributor.authorLogan, Theodore
dc.contributor.authorStadler, Walter M.
dc.contributor.authorMcCarthy, Philip L.
dc.contributor.authorLinker, Charles A.
dc.contributor.authorSmall, Eric J.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2022-12-08T22:40:14Z
dc.date.available2022-12-08T22:40:14Z
dc.date.issued2006-07-01
dc.description.abstractA graft-versus-tumor effect through nonmyeloablative allogeneic stem cell transplantation (N-SCT) in metastatic renal cell carcinoma (RCC) has been reported. An Intergroup phase II trial was undertaken to define further the feasibility, toxicity and efficacy of this approach in a multi-institutional setting, Patients with cytokine-refractory, metastatic RCC were treated with N-SCT. The conditioning regimen was fludarabine 30 mg · m−2 · d−1 on day (d) −7 through d −3 and cyclophosphamide 60 mg · kg−1 · d−1 on d −4 and d −3. Patients received 2-8 × 106 CD34+ cells/kg of granulocyte colony-stimulating factor mobilized stem cells from a 6/6 HLA-matched sibling donor. Immunosuppression after transplantation included tacrolimus and methotrexate. Twenty-two patients were enrolled at 14 institutions. Greater than 90% donor T-cell chimerism was observed in 17 of 19 evaluable patients (89%) by d +120. No objective response was observed. Acute graft-versus-host disease (GVHD) was observed in 11 patients (50%). Chronic GVHD was reported in 5 patients (23%). There was 1 patient death from liver failure secondary to chronic GVHD. Regimen-related mortality was 2 of 22 (9%; liver failure, sepsis). Median survival time was 5.5 months (95% confidence interval, 3.9-12.0 months) and the median time to progression was 3.0 months (95% confidence interval, 2.3-4.2 months). N-SCT for metastatic RCC is feasible in a multi-institutional setting. Adequate donor T-cell engraftment was achieved in most patients before disease progression. A graft-versus-tumor effect was not observed in this study despite acute and chronic GVHD, thus highlighting the need for further understanding of this approach. Allogeneic SCT remains investigational in RCC.en_US
dc.eprint.versionFinal published versionen_US
dc.identifier.citationRini, B. I., Halabi, S., Barrier, R., Margolin, K. A., Avigan, D., Logan, T., Stadler, W. M., McCarthy, P. L., Linker, C. A., & Small, E. J. (2006). Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Study. Biology of Blood and Marrow Transplantation, 12(7), 778–785. https://doi.org/10.1016/j.bbmt.2006.03.011en_US
dc.identifier.issn1523-6536en_US
dc.identifier.urihttps://hdl.handle.net/1805/30695
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.isversionof10.1016/j.bbmt.2006.03.011en_US
dc.relation.journalBiology of Blood and Marrow Transplantationen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0*
dc.sourcePublisheren_US
dc.subjectAllogeneicen_US
dc.subjectNonmyeloablative transplanten_US
dc.subjectRenal cell carcinomaen_US
dc.titleAdoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A CALGB Intergroup Phase II Studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Rini2006Adoptive-CCBYNCND.pdf
Size:
133.38 KB
Format:
Adobe Portable Document Format
Description:
Article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: